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Abstract 29 
The classification of neoplasms of adenohypophysial cells is misleading because of the 30 
simplistic distinction between adenoma and carcinoma based solely on metastatic spread and the 31 
poor reproducibility and predictive value of the definition of atypical adenomas based on 32 
detection of mitoses or expression of Ki-67 or p53. In addition, the current classification of 33 
neoplasms of the anterior pituitary does not accurately reflect the clinical spectrum of behavior.  34 
Invasion and regrowth of proliferative lesions, and persistence of hormone hypersecretion cause 35 
significant morbidity and mortality. We propose a new terminology, pituitary neuroendocrine 36 
tumor (PitNET), which is consistent with that used for other neuroendocrine neoplasms and 37 
which recognizes the highly variable impact of these tumors on patients.   38 
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Since the early work of Minkowski who attributed acromegaly to a pituitary tumor (1), 39 
neoplasms composed of pituitary adenohypophysial cells have been recognized as the cause of 40 
significant illness. However, Harvey Cushing attributed the term “adenoma” even to patients 41 
who died of their disease (2).   42 
We now recognize that these neoplasms are complex and heterogeneous; they present 43 
multiple clinical manifestations, including a wide range of proliferative and invasive behaviors 44 
(3).  Some are slowly-growing small lesions that are clinically insignificant, some are small or 45 
large hormonally active lactotroph tumors that respond to medical therapy with shrinkage and 46 
reduced hormone secretion, while other small and minimally proliferative lesions cause the 47 
severe metabolic dysfunction of Cushing’s disease or acromegaly.  Many are large and invasive 48 
neoplasms that cause significant morbidity due to mass effects, with or without hormone excess 49 
syndromes. Traditional classifications only recognize malignancy, denoted as pituitary 50 
carcinoma, when there is evidence of distant metastasis or cerebrospinal spread (4). The attempt 51 
to classify a subgroup as “atypical adenomas” based on detection of mitoses or expression of Ki-52 
67 or p53 (4) has proven to lack reproducibility and does not accurately predict recurrence or 53 
resistance to medical therapy (5).   Recently, a clinicopathological classification with five grades 54 
identified Grade 2b tumors as those with a high risk of recurrence or progression (6;7).  55 
However,  prediction of clinical aggressive behavior of these neoplasms, which occurs in 56 
approximately 10% of these tumors, remains debatable (8).  The term “adenoma”, which defines 57 
a tumor as benign, does not seem appropriate to define aggressive and invasive pituitary tumors 58 
that cannot be resected and are refractory to therapy.  59 
Patients and healthcare providers have long expressed frustration that these lesions are 60 
considered rare, benign, and inconsequential. In most jurisdictions they are not reported in cancer 61 
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registries. Pituitary patients are often denied access to and/or health insurance coverage for 62 
therapies that would be provided for “cancers”. 63 
The International Pituitary Pathology Club, created in 1981, is a group of expert 64 
pathologists, endocrinologists, neurosurgeons and scientists who meet on a regular basis to 65 
discuss challenges and advances in the pituitary field.  At the14th meeting in Annecy, France in 66 
November 2016, the subject of classification of these lesions was, as usual, controversial. 67 
However, there was consensus on one important aspect: pituitary endocrine neoplasms exhibit a 68 
spectrum of behaviors that are not entirely benign and can cause significant morbidity, even 69 
when they are not metastatic. 70 
We therefore propose a reclassification of these tumors to apply terminology that has 71 
been widely accepted in other neuroendocrine tumors (NETs) (4).  Pituitary hormone-producing 72 
cells are members of the family of neuroendocrine cells, similar to those of pancreatic islets, as 73 
well as dispersed endocrine cells of the gastrointestinal and respiratory tracts.  Over the last two 74 
decades, there have been terminology shifts that reflect the potential for malignant behavior of 75 
even the most bland of those neuroendocrine neoplasms. They evolved from “adenoma” to 76 
‘tumor” to recognize the lack of predictability.  We therefore propose that neoplasms of 77 
adenohypophysial cells be termed “pituitary neuroendocrine tumors”.  78 
Like other neuroendocrine neoplasms, many primary adenohypophysial tumors are 79 
indolent; they may be controlled by long-term pharmacologic treatment (e.g. dopamine-agonist 80 
therapy in the case of lactotroph tumors) or are non-invasive and cured by surgery. However, a 81 
variable proportion may recur despite remission.  In addition, a large proportion (40%) is 82 
invasive into the cavernous or sphenoid sinuses or cranial bones and cannot be totally removed 83 
by surgery. Moreover, some are resistant to the multiple medical treatments available, and are 84 
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considered to be clinically “aggressive”. The features distinguishing these behaviors are not 85 
entirely clear at this time and there is still no consensus on this matter.  Moreover, there is no 86 
biomarker that can reliably predict malignancy as defined by metastatic spread.  There is 87 
evidence that morphologic subtypes of pituitary neoplasms of the various cell lineages exhibit 88 
more aggressive behavior (8).  It is also clear that invasive lesions which cannot be surgically 89 
resected are likely to result in considerable morbidity (7); some may require radiotherapy or  are 90 
rapidly proliferative despite surgery, radiotherapy and/or medical therapy, requiring 91 
chemotherapy, for example temozolomide, or molecular targeted therapies. Accordingly, 92 
indications for novel therapies require elucidation of biomarkers that can guide personalized 93 
strategies. 94 
This revision of nomenclature is not intended to negate the classification by morphologic 95 
cell type, but instead is intended to change the classification to “tumor” rather than “adenoma”, 96 
for example, a “sparsely granulated somatotroph tumor” rather than “sparsely granulated 97 
somatotroph adenoma”.  The classification by morphologic cell type has been adopted by the 98 
World Health Organization (WHO) (4) and will remain in the next WHO classification that is 99 
underway.  Although the new terminology of “tumor” replacing “adenoma” will not be 100 
incorporated in the 2017 WHO book, this change, as with previous terminologies that 101 
transitioned to “NETs”, will be gradually adopted in order to be included in the next edition.  We 102 
hope that clarification of additional appropriate biomarkers will ultimately allow further 103 
refinement of the classification of pituitary neuroendocrine tumors.  104 
The authors of this statement feel strongly that the time has come to reclassify clonal 105 
adenohypophysial proliferations under the umbrella of “pituitary neuroendocrine tumor” 106 
(PitNET), a term that emphasizes the biological spectrum of these common endocrine 107 
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neoplasms.  Importantly, by analogy with other NETs, we encourage tumor registries to capture 108 
data on these tumors, thereby assisting efforts to clarify clinical and pathological features that 109 
can appropriately guide patient management. Pituitary neuroendocrine tumors are not simply 110 
endocrine diseases, but should be considered as tumors with endocrine manifestations within the 111 
context of oncology. 112 
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